In 2025, the drugmaker pledged $27 billion to build four new domestic pharmaceutical manufacturing sites three for active pharmaceutical ingredients (APIs) and one to manufacture parenteral (injectable) products and devices
Can Facial Volume Loss Be Prevented on GLP-1s
The relationship between GLP-1 receptor agonists and pre-existing gastrointestinal conditions requires careful clinical consideration, particularly given Wegovy's known effects on the digestive system
Some users say the texture changes depending on where they inject, with thighs and arms being more prone to lumps than the stomach
Social media is rife with anecdotes about tirzepatide and semaglutide as anti-consumption drugs affecting behaviors such as shopping and gambling further highlighting GLP-1RAs nascent potential for treating these issues
From a weight-loss perspective, and from a sugar-lowering perspective for those with Type 2 diabetes, we see stronger effects with Mounjaro compared to Ozempic, said Freeby, who was not involved in the research